Pharmaceutical leader Merck Research Laboratories recently finished a study on Keytruda (pembrolizumab), which can be used as a therapy for patients living with multiple myeloma, Hodgkin lymphoma, B-cell lymphoma and chronic lymphocytic leukemia.
Merck's researchers presented findings from the Keytruda study at the recent 57th American Society of Hematology (ASH) Annual Meeting.
“As part of our commitment to helping people with cancer, Merck is leading a broad immuno-oncology clinical program to evaluate the role of Keytruda across several types of blood cancer,” Dr. Roger Dansey, senior vice president at Merck Research Laboratories, said. “Despite the numerous advances in the treatment of blood cancers, there remains a significant unmet medical need. The findings presented at ASH are encouraging and reinforce the potential for Keytruda in the treatment of these types of cancer.”
Currently, Keytruda is used to treat more than 30 kinds of tumors. It has been the subject of more than 160 clinical trials.
More information on Keytruda and Merck's other products can be found online at the company's home page.
